We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Treatment for Smallpox

By Biotechdaily staff writers
Posted on 22 Sep 2005
Researchers have identified an antibody in humans that quickly fights the smallpox virus, representing a new treatment for the disease.

By studying blood samples from people who had received the smallpox vaccine, Shane Crotty, Ph.D., a viral disease expert, and his team at the La Jolla Institute for Allergy & Immunology (LIAI, San Diego, CA, USA) discovered the H3 protein, which elicits a particularly strong human antibody response. More...
Their findings were reported in the September 2005 issue of the Journal of Virology.

"Out of the 200 or so proteins contained in the smallpox virus, we found that the H3 protein is a major target for antibodies that kill the virus,” said Dr. Crotty. No actual smallpox virus was used in the studies in order to avoid any potential danger of transmission.

The research team used new techniques that made it easier to identify and isolate antibodies from the blood of immunized humans. Then they carefully screened for the antibodies that fight the smallpox virus. Next they tested their findings by creating a batch of the anti-H3 protein antibodies, which they injected into mice. "We were able to protect them from a strain of vaccinia pox virus that is very similar to smallpox and which is lethal to mice,” noted Dr. Crotty.

The U.S. National Institutes of Health (Bethesda, MD, USA) is now funding further research by Dr. Crotty to better understand the molecular processes surrounding the finding. One focus of the research will be to fully develop anti-H3 antibodies in the lab that can be given to humans.

"We will be working to further characterize and develop the use of this antibody as a treatment for smallpox,” added Dr. Crotty. "Unlike the vaccine, the antibody would work to provide immediate, although short-term, protection, similar to how an antibiotic treats and for a short time protects against a bacterial infection.”




Related Links:
La Jolla Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Platelet Function Analyzer
PL-12
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.